Forum Financial Management LP Has $2.56 Million Stock Position in Pfizer Inc. (NYSE:PFE)

Forum Financial Management LP increased its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 56.8% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 96,645 shares of the biopharmaceutical company's stock after acquiring an additional 35,001 shares during the period. Forum Financial Management LP's holdings in Pfizer were worth $2,564,000 as of its most recent filing with the SEC.

A number of other institutional investors have also made changes to their positions in the stock. Retirement Wealth Solutions LLC acquired a new position in shares of Pfizer during the 4th quarter worth about $26,000. Rialto Wealth Management LLC acquired a new position in shares of Pfizer during the fourth quarter worth approximately $26,000. Kohmann Bosshard Financial Services LLC bought a new stake in shares of Pfizer in the fourth quarter valued at approximately $28,000. Noble Wealth Management PBC acquired a new stake in shares of Pfizer in the fourth quarter worth $31,000. Finally, Curio Wealth LLC bought a new position in Pfizer during the fourth quarter worth $32,000. 68.36% of the stock is owned by institutional investors.

Insider Activity

In related news, Director Ronald E. Blaylock bought 19,457 shares of the business's stock in a transaction on Thursday, February 13th. The shares were purchased at an average price of $25.65 per share, with a total value of $499,072.05. Following the completion of the purchase, the director now owns 27,707 shares of the company's stock, valued at $710,684.55. This represents a 235.84 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 0.06% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on PFE. Guggenheim restated a "buy" rating on shares of Pfizer in a report on Tuesday, March 18th. Hsbc Global Res raised Pfizer to a "strong-buy" rating in a report on Monday, March 10th. Cantor Fitzgerald began coverage on Pfizer in a report on Tuesday. They set a "neutral" rating and a $24.00 price objective on the stock. The Goldman Sachs Group restated a "neutral" rating and issued a $25.00 target price (down from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. Finally, Citigroup reiterated a "neutral" rating on shares of Pfizer in a research note on Thursday, March 27th. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating, five have issued a buy rating and three have issued a strong buy rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $29.57.

Pfizer Price Performance

Shares of PFE traded down $0.14 on Wednesday, hitting $22.39. The company's stock had a trading volume of 29,719,282 shares, compared to its average volume of 40,414,729. The company has a 50 day moving average price of $24.75 and a 200 day moving average price of $26.08. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $31.54. The company has a market capitalization of $126.98 billion, a PE ratio of 15.88, a PEG ratio of 0.64 and a beta of 0.67. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73.

Pfizer (NYSE:PFE - Get Free Report) last announced its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, topping the consensus estimate of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company had revenue of $17.76 billion for the quarter, compared to analysts' expectations of $17.26 billion. During the same quarter in the prior year, the business earned $0.10 earnings per share. The business's revenue for the quarter was up 24.7% on a year-over-year basis. On average, research analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.